INCY vs MEDP stock comparison
Incyte vs. Medpace · data as of November 13, 2026
Incyte (INCY) has a market value of about $24.7B, Medpace (MEDP) about $18.3B. Over their latest twelve months Incyte had revenue of $6.0B and Medpace $2.8B.
On our five checks Medpace scores higher: 3.2 out of 5 (average) against 2.8 (average).
By area, the stronger company is Medpace on value; Medpace on track record; Incyte on financial health.
Medpace is cheaper on earnings (P/E 36.3 vs. 61.7).
Incyte leads on 6 of the compared lines and Medpace on 12.
Side by side
| INCY | MEDP | |
|---|---|---|
| Size and price | ||
| Market cap | $24.7B | $18.3B |
| Share price | $120.97 | $653.94 |
| Score | ||
| Overall score (of 5) | 2.8 | 3.2 |
| Value | 0 | 1 |
| Future growth | 4 | 4 |
| Track record | 3 | 5 |
| Financial health | 5 | 4 |
| Shareholder returns | 2 | 2 |
| Valuation | ||
| P/E (TTM) | 61.7 | 36.3 |
| Forward P/E | 15.1 | 33.6 |
| Price / free cash flow | 36.3 | 27.4 |
| Price / sales | 4.1 | 6.4 |
| EV / EBITDA | 29.5 | 27.9 |
| PEG | — | 1.14 |
| DCF value vs. price | −48% | −32% |
| Business | ||
| Revenue | $6.0B | $2.8B |
| Net income | $403M | $518M |
| Free cash flow | $680M | $668M |
| Net margin | 6.7% | 18.2% |
| Gross margin (5-yr avg.) | 93.5% | — |
| ROIC (5-yr avg.) | 10.6% | 41.9% |
| Growth | ||
| Revenue growth (1 yr) | 21.2% | 20.0% |
| Revenue growth (5 yrs, per year) | 14.0% | 22.3% |
| EPS growth (5 yrs, per year) | — | 31.8% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | — | — |
| Dividend yield | None | None |
| Shareholder yield | 0.0% | 5.0% |
| Analysts | ||
| Upside to average target | +9% | −0% |
| Consensus rating | Buy | none |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: INCY TTM to September 30, 2026, MEDP TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Incyte or Medpace?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Medpace scores 3.2 out of 5 and Incyte 2.8; the table shows where each one is stronger.
Is Incyte cheaper than Medpace?
On trailing earnings, Medpace trades at a P/E of 36.3 and Incyte at 61.7, so Medpace is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Incyte or Medpace?
Over five years Medpace grew revenue about 22.3% a year and Incyte about 14.0% a year.
Full Incyte analysis → Full Medpace analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.